aid: initial-therapeutics
name: Initial Therapeutics
description: >-
  Initial Therapeutics, Inc. is a preclinical-stage biotechnology company in South San
  Francisco, California, discovering and developing a new class of small-molecule medicines
  designed to halt pathogenic protein formation in its earliest stages. Its proprietary STOPS
  platform — Selective Termination of Protein Synthesis — intercepts the translation of a target
  protein inside the exit tunnel of the ribosome, recognizing the nascent primary linear sequence
  rather than a fully folded three-dimensional structure, an approach the company positions as
  starkly differentiated from targeted protein degradation and from interventions that can only
  act on proteins after they are fully formed. The company launched publicly on May 1, 2023 with
  a $75 million Series A from Apple Tree Partners, was co-founded with academic scientists Jamie
  H. D. Cate (UC Berkeley), Brian Paegel (UC Irvine) and Kevan Shokat (UCSF/UC Berkeley), and
  builds on ribosome biochemistry, proteomics, medicinal chemistry, DNA-encoded library technology
  and chemical genetics, with early programs aimed at oncology targets long considered undruggable.
  Initial Therapeutics is a therapeutics discovery company, not a software vendor: it publishes a
  small marketing website and no public API, SDK, developer portal or machine-readable contract of
  any kind.
url: https://raw.githubusercontent.com/api-evangelist/initial-therapeutics/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: harvest
specificationVersion: '0.20'
created: '2026-08-23'
modified: '2026-08-23'
tags:
- Company
- Biotechnology
- Therapeutics
- Drug Discovery
- Small Molecules
- Oncology
- Life Sciences
- Preclinical
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/initial-therapeutics-domain-security.yml
- type: Website
  url: https://initialtx.com/
- type: TermsOfService
  url: https://initialtx.com/terms-of-use.html
- type: PrivacyPolicy
  url: https://initialtx.com/privacy-policy.html
- type: LLMsTxt
  url: llms/initial-therapeutics-llms.txt

x-enrichment:
  date: '2026-08-23'
  status: minimal
  artifacts_added: 3
  pass: local-v1

x-coverage:
  state: none
  reason: not-a-software-company
  detail: >-
    Initial Therapeutics is a preclinical small-molecule drug-discovery company whose entire web
    presence is a five-page marketing site on shared SiteGround hosting, where every contract path
    (/openapi.json, /graphql, /llms.txt, /.well-known/*) returns the identical site-wide HTTP 202
    robot-challenge body that a deliberately bogus path returns, and api./docs./developer.initialtx.com
    are wildcard DNS onto SiteGround's default vhost (403, certificate CN=gvam1148.siteground.biz) —
    there is no API here to gate, to read, or to hide.
  evidence:
  - url: https://initialtx.com/openapi.json
    status: 202
  - url: https://initialtx.com/.well-known/agent-card.json
    status: 202
  - url: https://api.initialtx.com/openapi.json
    status: 403
  - url: https://pypi.org/pypi/initialtx/json
    status: 404
  checked: '2026-08-23'